Navigation Links
ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
Date:6/7/2010

Chicago, IL and San Jose, CA, June 7, 2010 Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. In this new study of 575 individuals, Chronix's proprietary assays detected and identified DNA fingerprints in the blood that indicated the presence of prostate cancer and breast cancer with 92% sensitivity and 100% specificity, significantly outperforming the published accuracy data for current diagnostic methods. The new study results were presented in an oral session today at the 2010 ASCO Annual Meeting in Chicago.

Breast cancer expert, Steven Narod, M.D., F.R.C.P.C., noted, "These new data, although early, provide further evidence that Chronix's proprietary serum DNA assays may represent a new diagnostic and prognostic platform that can identify cancer earlier and more accurately than is currently possible. I am pleased to be working with Chronix to further validate these promising findings." Dr. Narod is Director of the Familial Breast Cancer Research Unit at Women's College Research Institute, an affiliate of the University of Toronto.

The tests use proprietary algorithms developed by Chronix researchers to detect, analyze and identify cancer-related fragments of circulating DNA that are released into the bloodstream by apoptotic cells. Chronix researchers consistently find that this apoptotic DNA in the serum is coming from a limited number of regions or "hotspots" on the genome specific to each cancer. According to the data presented today, DNA fragments from any one of the 29 breast cancer "hotspots" and 32 prostate cancer "hotspots" identified by Chronix researchers indicate that cancer is present.

"By focusing on these blood-borne genomic 'hotspots,' we can reliably detect the presence of cancer without having to first isolate or analyze the tumor cells," said Howard Urnovitz, Ph.D., Chief Executive Officer of Chronix and a co-author of the study. "If verified by further studies, our Chronix blood-based assays would make it possible to diagnose cancer at its earliest stages, track progress as patients undergo treatment and possibly even optimize treatment using patients' disease-specific genomic fingerprints."

The testing involved 575 individuals: 178 with early stage breast cancer, 197 with invasive prostate cancer and 200 healthy controls. The Chronix assays detected breast cancer with a 92% sensitivity and 100% specificity. Although not directly comparable, for reference it is noteworthy that data from a large study of U.S. mammography screening programs reported an overall sensitivity of just 75%, and specificity of 92.3%, with lower figures for some populations such as younger women. The Chronix assays also detected invasive prostate cancer with a 92% sensitivity and 100% specificity. In contrast, the widely used PSA (prostate specific antigen) test has previously demonstrated 85% sensitivity and a specificity of just 25% to 35%. If the Chronix data are confirmed in larger studies, they have the potential to reduce the current rate of false positive and false negative results that contribute to poorer patient outcomes and higher health care costs.

Previous published studies have demonstrated that the Chronix approach can identify the presence or absence of active disease in multiple sclerosis patients and that it can accurately detect early stage breast cancer with high diagnostic sensitivity and specificity. Commercial applications for veterinary use are already in development in conjunction with the University of Calgary, including tests for the early detection of BSE, or mad cow disease.

Dr. Urnovitz added, "With these encouraging findings, we are launching a 'For Investigative Use Only' testing service that for the first time will enable cancer researchers to monitor the status of patients in their clinical trials with a high level of sensitivity and specificity, potentially accelerating clinical trials and increasing their chances for success."

Patient data collected from this new service for clinical researchers along with additional planned clinical studies are expected to expand the database needed to obtain regulatory approval for the use of Chronix assays in ongoing cancer patient care.


'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

Related medicine news :

1. Cosmetic Peptides that Significantly Reduce Length and Depth of Wrinkles: Janet Sartin Introduces Advanced Anti-Wrinkle Peptide Serum for All Skin Types
2. Blood stem-cell transplant regimen reverses sickle cell disease in adults
3. Blood Thinner Combos Risky for Heart Attack Patients
4. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
5. A better sign of blood vessel narrowing and early coronary artery disease
6. American Red Cross and Other U.S. Blood Centers Send Blood to Haiti
7. Analysis Examines Ultrasound Use for Blood Clots
8. Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive
9. Newly discovered mechanism by which blood clots form
10. Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis
11. Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology: